Abbvie-Header Abbvie-Header

X

Find Drugs for Cardiology/Vascular Diseases in Phase III Clinical Development in CANADA

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Apabetalone

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: RVX-208

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 12, 2021

            Details:

            In BETonMACE study, significantly fewer hospitalizations for heart failure (HHF) in patients with type 2 diabetes and a recent history of acute coronary syndrome (ACS) were observed in the apabetalone treatment group compared to placebo.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Etripamil

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: MSP-2017

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Jefferies and Piper Sandler

            Deal Size: $45.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering October 23, 2020

            Details:

            Milestone intends to use the net proceeds from the offering primarily to fund the clinical development of its lead product candidate etripamil, and for general corporate purposes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Omega-3 phospholipid

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Capre

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 31, 2020

            Details:

            Top-line results for the Primary Endpoint (triglyceride reduction at 12 and 26 weeks) from its 278 patient Phase 3 TRILOGY 2 study evaluating the efficacy, safety and tolerability of CaPre in patients with severe hypertriglyceridemia.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Omega-3 phospholipid

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Capre

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 31, 2020

            Details:

            Analysis of the TRILOGY 1 data revealed a rapid, significant and sustained reduction in Triglyceride levels between screening and the time of patient randomization, which Acasti refers to as “Pre-randomization Triglyceride Normalization.